stoxline Quote Chart Rank Option Currency Glossary
Aldeyra Therapeutics, Inc. (ALDX)
3.89  0.12 (3.18%)    06-12 16:00
Open: 3.87
High: 4.045
Volume: 361,054
Pre. Close: 3.77
Low: 3.845
Market Cap: 231(M)
Technical analysis
2024-06-12 4:20:16 PM
Short term     
Mid term     
Targets 6-month :  4.79 1-year :  5.11
Resists First :  4.1 Second :  4.38
Pivot price 3.87
Supports First :  3.65 Second :  3.04
MAs MA(5) :  3.86 MA(20) :  3.91
MA(100) :  3.66 MA(250) :  4.65
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  29.7 D(3) :  32.3
RSI RSI(14): 49.1
52-week High :  11.97 Low :  1.41
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ALDX ] has closed below upper band by 46.7%. Bollinger Bands are 49.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.05 - 4.08 4.08 - 4.1
Low: 3.79 - 3.82 3.82 - 3.85
Close: 3.85 - 3.9 3.9 - 3.93
Company Description

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Headline News

Wed, 12 Jun 2024
Aldeyra Therapeutics to Host Investor Roundtable Q&A - Business Wire

Wed, 05 Jun 2024
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Sold by Eagle Asset Management Inc. - Defense World

Wed, 29 May 2024
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference - Business Wire

Tue, 14 May 2024
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Thu, 25 Apr 2024
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis ... - BioSpace

Mon, 08 Apr 2024
Perceptive advisors buys Aldeyra Therapeutics shares worth $833k By -

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 59 (M)
Shares Float 43 (M)
Held by Insiders 2.4 (%)
Held by Institutions 61.3 (%)
Shares Short 2,360 (K)
Shares Short P.Month 2,360 (K)
Stock Financials
EPS -0.51
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.9
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -14.3 %
Return on Equity (ttm) -24 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.6
Qtrly Earnings Growth 0 %
Operating Cash Flow -31 (M)
Levered Free Cash Flow -84 (M)
Stock Valuations
PE Ratio -7.63
PEG Ratio -0.4
Price to Book value 2.03
Price to Sales 0
Price to Cash Flow -7.5
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android